Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 2
2000 1
2001 2
2014 4
2015 1
2016 1
2017 2
2018 1
2019 2
2020 3
2021 7
2022 6
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Response letter to the Editor.
Conaghan PG, Guehring H, Moreau F, Daelken B, Ladel C, Guenther O, Reinstrup Bihlet A, Wirth W, Eckstein F, Hochberg M. Conaghan PG, et al. Among authors: guehring h. Semin Arthritis Rheum. 2022 Feb;52:151839. doi: 10.1016/j.semarthrit.2021.05.001. Epub 2021 May 8. Semin Arthritis Rheum. 2022. PMID: 34006385 Free article. No abstract available.
Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis.
Montalban X, Wallace D, Genovese MC, Tomic D, Parsons-Rich D, Le Bolay C, Kao AH, Guehring H. Montalban X, et al. Among authors: guehring h. J Neurol Neurosurg Psychiatry. 2023 Jan;94(1):1-9. doi: 10.1136/jnnp-2022-328799. Epub 2022 Nov 23. J Neurol Neurosurg Psychiatry. 2023. PMID: 36418156 Free PMC article. Clinical Trial.
Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial.
Wallace DJ, Dörner T, Pisetsky DS, Sanchez-Guerrero J, Patel AC, Parsons-Rich D, Le Bolay C, Drouin EE, Kao AH, Guehring H, Dall'Era M. Wallace DJ, et al. Among authors: guehring h. ACR Open Rheumatol. 2023 Jan;5(1):38-48. doi: 10.1002/acr2.11511. Epub 2022 Dec 18. ACR Open Rheumatol. 2023. PMID: 36530019 Free PMC article.
Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future.
Karsdal MA, Michaelis M, Ladel C, Siebuhr AS, Bihlet AR, Andersen JR, Guehring H, Christiansen C, Bay-Jensen AC, Kraus VB. Karsdal MA, et al. Among authors: guehring h. Osteoarthritis Cartilage. 2016 Dec;24(12):2013-2021. doi: 10.1016/j.joca.2016.07.017. Epub 2016 Aug 2. Osteoarthritis Cartilage. 2016. PMID: 27492463 Free article. Review.
Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS, Seitzinger A, Guehring H, Shaw J, Tomic D, Hyvert Y, Harlow DE, Dyroff M, Wolinsky JS. Montalban X, et al. Among authors: guehring h. Mult Scler. 2024 Apr;30(4-5):558-570. doi: 10.1177/13524585241234783. Epub 2024 Mar 4. Mult Scler. 2024. PMID: 38436271 Clinical Trial.
32 results